Inagaki Koji, Yasuda Yoshinari, Ando Masahiko, Kaihan Ahmad Baseer, Hachiya Asaka, Ozeki Takaya, Hishida Manabu, Imaizumi Takahiro, Katsuno Takayuki, Kato Sawako, Tsuboi Naotake, Maruyama Shoichi
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
PLoS One. 2017 Nov 2;12(11):e0187607. doi: 10.1371/journal.pone.0187607. eCollection 2017.
Proteinuria is a powerful prognostic factor for end-stage renal disease in IgA nephropathy (IgAN) patients. However, it is not known whether proteinuria exacerbations are related to seasonal changes.
We retrospectively enrolled consecutive patients diagnosed with IgAN by kidney biopsy at our hospital between 2002 and 2014. Proteinuria remission was defined as urinary protein <0.3 g/gCr in two consecutive outpatient urinalyses and exacerbation as urinary protein ≥0.75 g/gCr. Four seasons were defined: spring (March-May), summer (June-August), autumn (September-November), and winter (December-February). We performed a multivariate analysis to identify factors associated with the second remission following a proteinuria exacerbation.
We analyzed 116 patients. Proteinuria remission and exacerbation occurred in 77, and 43 patients, respectively. The incidence of proteinuria exacerbation was significantly higher in autumn and winter than in spring and summer (p = 0.040). The cumulative second remission rate was significantly higher in patients with autumn and winter proteinuria exacerbation than in patients with spring and summer exacerbations (p = 0.0091). In multivariate analyses, exacerbation onset in autumn and winter (hazard ratio [HR], 3.51; 95% confidence interval [CI], 1.41-8.74) and intensive therapy (HR, 2.26; 95% CI, 1.05-4.88) were significantly associated with a second proteinuria remission.
In IgAN patients in proteinuria remission, proteinuria exacerbation frequently occurred in autumn and winter. Exacerbations occurring in autumn and winter tended to remit early.
蛋白尿是IgA肾病(IgAN)患者终末期肾病的一个强有力的预后因素。然而,尚不清楚蛋白尿加重是否与季节变化有关。
我们回顾性纳入了2002年至2014年间在我院经肾活检确诊为IgAN的连续患者。蛋白尿缓解定义为连续两次门诊尿液分析中尿蛋白<0.3 g/gCr,加重定义为尿蛋白≥0.75 g/gCr。定义了四个季节:春季(3月至5月)、夏季(6月至8月)、秋季(9月至11月)和冬季(12月至2月)。我们进行了多变量分析,以确定与蛋白尿加重后第二次缓解相关的因素。
我们分析了116例患者。分别有77例和43例患者出现蛋白尿缓解和加重。秋季和冬季蛋白尿加重的发生率显著高于春季和夏季(p = 0.040)。秋季和冬季蛋白尿加重的患者累积第二次缓解率显著高于春季和夏季加重的患者(p = 0.0091)。在多变量分析中,秋季和冬季的加重发作(风险比[HR],3.51;95%置信区间[CI],1.41 - 8.74)和强化治疗(HR,2.26;95%CI,1.05 - 4.88)与第二次蛋白尿缓解显著相关。
在蛋白尿缓解的IgAN患者中,蛋白尿加重常见于秋季和冬季。秋季和冬季发生的加重倾向于早期缓解。